Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 12/20 | 0.70 |
| ▸ | RARB | P10826 | 11/20 | 0.70 |
| ▸ | RARA | P10276 | 11/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.70 |
| ▸ | GOT1 | P17174 | 1/20 | 0.70 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30153290 | 1.00 | RARG (0.70) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL7077350 | 0.89 | RARB (0.61) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL8766163 | 0.86 | RARG (0.74) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL30817478 | 0.85 | RARB (0.49) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL5081246 | 0.84 | RARB (0.74) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL8767123 | 0.84 | RARG (0.70) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL22929249 | 0.83 | RARB (0.69) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL30015507 | 0.83 | RARB (0.69) | RARGRARBRARAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8765869 | 0.83 | RARG (0.69) | RARGRARBRARAMEN1KMT2A | |
| SCHEMBL980744 | 0.83 | RARB (0.72) | RARGRARBRARAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4066826-B1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS FOR MUSCLE REPAIR AND REGENERATION | UNIV JEFFERSON (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4066826-A1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS FOR MUSCLE REPAIR AND REGENERATION | Thomas Jefferson University (US) | 2022-10-05 | — | — | EP | claimed |
| US-11433039-B2 | Composition and method for muscle repair and regeneration | THOMAS JEFFERSON UNIVERSITY (US) | 2022-09-06 | — | — | US | claimed |
| EP-2613776-B1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | UNIV JEFFERSON (US) | 2020-07-29 | — | — | EP | claimed |
| US-20200069620-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY | 2020-03-05 | — | — | US | claimed |
| US-9789074-B2 | Composition and method for muscle repair and regeneration | THOMAS JEFFERSON UNIVERSITY (US) | 2017-10-17 | — | — | US | claimed |
| US-20140363402-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY (US) | 2014-12-11 | — | — | US | claimed |
| EP-2613776-A2 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | Thomas Jefferson University (US) | 2013-07-17 | — | — | EP | claimed |
| WO-2012030919-A2 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY (US) | 2012-03-08 | — | — | WO | claimed |
| US-6686386-B1 | COMBATING PHOTOINDUCED OR CHRONOLOGICAL AGEING OF SKIN WITH RETENOIC ACID RECEPTOR AGONIST | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-03 | — | — | US | claimed |
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-05-15 | — | — | US | claimed |
| US-20010018456-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | FESUS LASZLO (HU) | 2001-08-30 | — | — | US | claimed |
| US-20250108022-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY | 2025-04-03 | — | — | US | disclosed |
| US-12023312-B2 | Composition and method for muscle repair and regeneration | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-02 | — | — | US | disclosed |
| EP-4066826-B1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS FOR MUSCLE REPAIR AND REGENERATION | UNIV JEFFERSON (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230346727-A1 | COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA | UNIVERSITE GRENOBLE ALPES (FR) | 2023-11-02 | — | — | US | disclosed |
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-05-15 | — | — | US | disclosed |
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 2003-05-15 | — | — | US | disclosed |
| US-6506796-B1 | Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2003-01-14 | — | — | US | disclosed |
| US-20010018456-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | FESUS LASZLO (HU) | 2001-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346727-A1 | COMPOUNDS FOR THE TREATMENT OF HEMOPHILIA | PROC, F2, F8 | RARG 1713/4885RARB 1848/4885RARA 1675/4885 |
| US-20030092758-A1 | Use of a RAR-gamma-specific agonist ligand for increasing the rate of apoptosis | RARA, RARB, RARG | RARG 3/4885RARB 2/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.